Melissa Alsina

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma”.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

New England Journal of Medicine(2022)10.1056/nejmoa2204925

N/A

6.2DataRank · unranked

474 citations

Susanna Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur Raje +51 more

Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma

Research Square(2025)10.21203/rs.3.rs-6306816/v1

N/A

0.104DataRank · unranked

1 citations

Rafael Renatino Canevarolo, Praneeth Sudalagunta, Mark B. Meads, Maria João Silva, Xiaohong Zhao +29 more

The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7003

N/A

0DataRank · unranked

2 citations

Qaiser Bashir, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina +11 more

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.007

N/A

0DataRank · unranked

9 citations

T Nishihori, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina +15 more

Data from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

(2023)10.1158/0008-5472.c.6500067.v1

N/A

0DataRank · unranked

0 citations

Vasco Oliveira, Linda Mathews, Xingyu Wang, Alejandro Villagra, David R. Boulware +7 more

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Blood(2024)10.1182/blood.2024025945

N/A

0DataRank · unranked

130 citations

Krina K. Patel, Lauren C. Peres, Radhika Bansal, Mehmet H. Kocoglu, Leyla Shune +33 more